Avidity Biosciences, Inc. (RNAM) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-02-27

Avidity Biosciences, Inc. (RNAM) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every RNAM SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Avidity Biosciences, Inc. (RNAM)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001599901

Recent RNAM Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-02-27	Kim Jean Jinsun	Insider	D — Derivative transaction	6.7K	—	—	SEC
2026-02-27	LEVIN ARTHUR A	Insider	D — Derivative transaction	16.6K	—	—	SEC
2026-02-27	Henig Noreen	Insider	D — Derivative transaction	6.7K	—	—	SEC
2026-02-27	Gallagher Kathleen P.	Chief Program Officer	D — Derivative transaction	80.3K	—	—	SEC
2026-02-27	WILSON TROY EDWARD	Insider	D — Derivative transaction	13.7K	—	—	SEC
2026-02-27	Moriarty John B	Chief Legal Officer	D — Derivative transaction	92.1K	—	—	SEC
2026-02-27	WILSON TROY EDWARD	Insider	D — Derivative transaction	65.1K	—	—	SEC
2026-02-27	MacLean Michael F	Chief Financial Officer	D — Derivative transaction	134.0K	—	—	SEC
2026-02-27	Thompson Tamar	Insider	D — Derivative transaction	6.7K	—	—	SEC
2026-02-27	McCarthy Teresa	Chief Human Resources Officer	D — Derivative transaction	165.3K	—	—	SEC
2026-02-27	Flanagan W. Michael	Chief Scientific Officer	D — Derivative transaction	150.4K	—	—	SEC
2026-02-27	Skerjanec Simona	Insider	D — Derivative transaction	6.7K	—	—	SEC
2026-02-27	Hughes Steven George	Chief Medical Officer	D — Derivative transaction	115.9K	—	—	SEC
2026-02-27	Boyce Sarah	President and CEO	D — Derivative transaction	474.9K	—	—	SEC
2026-02-27	LEVIN ARTHUR A	Insider	D — Derivative transaction	131.4K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Avidity Biosciences, Inc. (RNAM). Updated in real time as new filings are submitted to the SEC.

Recent RNAM Form 8-K Material Events

2026-02-27 — Item 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 · Acquisition · neutral [SEC]
Avidity Biosciences' merger with Novartis subsidiary Ajax Acquisition Sub was completed on February 27, 2026, with Avidity shareholders receiving $72.00 per share in cash. This is an administrative closing of a deal that was announced on October 25, 2025, and the stock price alre
2026-02-26 — Item 5.07 · Acquisition · neutral [SEC]
Avidity Biosciences stockholders voted to approve a previously announced merger with Novartis and a concurrent spinoff of Atrium Therapeutics (formerly Bryce Therapeutics). The vote passed with 99.99% approval (123.4M votes for vs 8,090 against). This is a procedural filing confi
2026-02-23 — Item 8.01, 9.01 · Acquisition · neutral [SEC]
Avidity Biosciences announced the final procedural steps for its previously announced merger with Novartis, including adjournment and reconvening of the special stockholder meeting on February 26, 2026, with merger closing expected February 27, 2026. This is an administrative fol

Recent Insider Filings

2026-02-27 — McCarthy Teresa (Chief Human Resources Officer)
2026-02-27 — Thompson Tamar (Insider)
2026-02-27 — MacLean Michael F (Chief Financial Officer)
2026-02-27 — Skerjanec Simona (Insider)
2026-02-27 — Hughes Steven George (Chief Medical Officer)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in RNAM insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

RNAM Insider Trading — FAQ

What is the latest insider trade for RNAM?: Avidity Biosciences, Inc. (RNAM) had 0 insider filings in the last 90 days, with the most recent on 2026-02-27. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying RNAM stock?: 0 insider purchases of RNAM were filed in the last 90 days.
How many insiders are selling RNAM stock?: 0 insider sales of RNAM were filed in the last 90 days.
Where can I see RNAM SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every RNAM SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live RNAM dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.